ENHERTU® RECOMMENDED FOR APPROVAL IN THE EU BY CHMP AS ADJUVANT TREATMENT FOR PATIENTS WITH RESIDUAL DISEASE AFTER NEOADJUVANT TREATMENT FOR HER2 POSITIVE EARLY BREAST CANCER

Reuters · 2d ago

Please log in to view news